Skip to main content

Clinical trial ICON

A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

Organ sein
Trial status Trial open for recruitment
Trial type
Interventionnal with IMP
Phase Trial phase 2
Academic trial Oui
Sponsor Oslo University Hospital
EudraCT Identifier 2017-000220-10
Inclusion criteria ER+/HER2-. Metastatic
Last update